Research & Development
-
Getty Images
GondolaBio gives new meaning to ‘sweat equity’ in rare R&D
Instead of investing cash, Children’s Tumor Foundation is offering its clinical expertise and scientific infrastructure in exchange for an equity stake in GondolaBio’s preclinical drug program.
By Alexandra Pecci • Nov. 10, 2026 -
Jeenah Moon via Getty Images
Making MovesPfizer’s comeback gets a new finance chief
Cecile Guegan just became Pfizer’s first permanent female CFO as the large pharma navigates its major pipeline bets in obesity.
By Meagan Parrish • Nov. 10, 2026 -
Explore the Trendline➔
Getty Images
TrendlineTech for Clinical Trials
Companies that utilize these emerging technologies wisely are likely to find an edge in the increasingly competitive drug development arena.
By PharmaVoice staff -
Permission granted by Cytiva
Sponsored by CytivaHow can we build trust in model-driven manufacturing?
Predict, optimize and act sooner with model-driven bioprocessing.
By Martin Ball, Senior Product Marketing Manager, Automation and Digital, Cytiva • Nov. 9, 2026 -
Sarah Silbiger via Getty Images
A push for speedier drug approvals doesn’t promise smooth market sailing
Investors and payers sometimes balk at drugs approved on an accelerated pathway. Here’s how pharma can de-risk these medications while they’re still in development.
By Alexandra Pecci • Nov. 4, 2026 -
Jamie McCarthy via Getty Images
Lilly’s R&D whirlwind — what the large pharma has taken in and what it’s dropped
While its GLP-1 franchise is still booming, prospects in other arenas haven’t panned out. Here’s a look at where Lilly’s investing the candidates it’s recently had to drop.
By Kelly Bilodeau • Nov. 3, 2026 -
Permission granted by Johnson & Johnson
Q&AHow well is J&J’s incubator model working?
After incubating about 1,200 companies, the pharma giant is putting less emphasis on physical lab space — and taking a more targeted approach to new science.
By Meagan Parrish • Nov. 2, 2026 -
Permission granted by Merck & Co.
Keytruda biosims are coming — but they face an uphill battle
The dreaded patent cliff is fast approaching for Merck’s flagship blockbuster, but the deck might be stacked against its biosimilars gaining widespread traction.
By Kelly Bilodeau • Oct. 30, 2026 -
Getty Images
Anthropic’s historic IPO; Akeso’s big clinical showing
Anthropic is setting the stage for the largest IPO in history and Akeso has been touting its latest positive results for its buzzy bispecific.
By PharmaVoice Staff • Oct. 30, 2026 -
Getty Images
What a cancer survivor sees that AI could miss in trial design
Parexel’s Stacy Hurt draws on her experience with chemotherapy and as a caregiver to spot patient burdens that AI-assisted protocol design can overlook.
By Kelly Bilodeau • Oct. 28, 2026 -
Getty Images
What 3 multibillion dollar biotechs still have to prove
Summit, Abivax and Viking have lofty valuations but no FDA-approved products. Each faces a different test of its clinical promise and commercial potential.
By Meagan Parrish • Oct. 27, 2026 -
Permission granted by Courtesy of Immunic Therapeutics
MS has plenty of drugs. This Ocrevus veteran sees what’s missing.
After helping launch a blockbuster Roche and Genentech therapy, Erik Lundgren is betting Immunic's experimental drug can address persistent gaps in MS care, with pivotal trial results approaching.
By Alexandra Pecci • Oct. 26, 2026 -
Getty Images
A cancer drug worked in the lab — but not how scientists thought
Researchers uncovered the unexpected mechanism behind a cancer drug candidate, highlighting a persistent problem in drug discovery.
By Kelly Bilodeau • Oct. 23, 2026 -
Getty Images
Drug discovery is speeding up. But clinical trials are buckling under their own weight.
A growing pipeline is colliding with tougher recruitment, more demanding protocols and trial operations struggling to keep pace — and AI alone can’t fix it.
By Sy Mukherjee • Oct. 22, 2026 -
Pete Marovich via Getty Images
A CEO, an ex-CDC director and an ex-FDA commissioner walk into a biotech…
Dr. Robert Redfield and Dr. Stephen Hahn came aboard Turn Therapeutics this year to help the clinical-stage company develop a platform that could one day change how vaccines are delivered.
By Kelly Bilodeau • Oct. 21, 2026 -
Getty Images
Biotech is booming — and startups are still dying
Despite an uptick in dealmaking and IPOs, a selective funding market and scientific setbacks are still pushing some biotechs to the brink.
By Meagan Parrish • Oct. 19, 2026 -
Getty Images
Q&AAlzheimer’s trials need patients. Why are so many screened out?
A new report argues that more flexible eligibility criteria could widen pharma’s clinical trial pool without sacrificing safety.
By Kelly Bilodeau • Oct. 16, 2026 -
Getty Images
FDA ‘reset’ continues with new plan for reviewing rare disease drugs
A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one analyst said.
By Kristin Jensen • Oct. 16, 2026 -
Getty Images
Hype vs. reality: What pharma’s hottest R&D bets have actually proved
New types of bispecifics, ADCs and CAR-Ts are still proving themselves in the clinic — pharma’s betting billions anyway.
By Sy Mukherjee • Oct. 15, 2026 -
Getty Images
Q&A // Biotech SpotlightA new startup takes aim at a suspected culprit in autoimmune disease
Ai3Bio recently emerged from stealth with preclinical programs aimed at what it believes could be a root cause of autoimmune conditions: diseased T cells.
By Kelly Bilodeau • Oct. 14, 2026 -
Getty Images
HHS’ need for R&D speed; weird GLP-1 side effects
HHS is cranking up its efforts to accelerate drug development; more reports are emerging about off target effects of obesity drugs.
By PharmaVoice Staff • Oct. 9, 2026 -
Permission granted by Merck & Co.
ProfileA day in the life of a Merck R&D chief
Dr. Eliav Barr pulls back the curtain on what it's like to manage Merck’s fast-growing pipeline.
By Meagan Parrish • Oct. 9, 2026 -
Getty Images
5 key facts about the FDA expedited IND pilot program
The program, part of Operation TrialBlazer, aims to speed early research and help the U.S. bring trials back from overseas.
By Kelly Bilodeau • Oct. 7, 2026 -
Getty Images
Top pharma industry conferences in 2027
Where pharma and biotech leaders will converge to network, share ideas and potentially strike deals.
By Meagan Parrish • Oct. 6, 2026 -
Getty Images
The next frontier in obesity drugs: lasting weight loss
Alveus, Lilly, Viking and Amgen are testing maintenance strategies as durability becomes a bigger focus in obesity R&D.
By Kelly Bilodeau • Oct. 6, 2026 -
Permission granted by Daiichi Sankyo
Q&AWill there be more to Daiichi’s story than DXd ADCs?
Dr. John Tsai grabbed the reins of global R&D this year with a clear mandate: extend Daiichi’s oncology momentum beyond its DXd franchise.
By Meagan Parrish • Oct. 5, 2026
